Drug Trial Radar · NCT05933265
Study of LP-184 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
64
Actual
Start
Jun 9, 2023
Primary completion
Jul 28, 2026
Study completion Jul 28, 2026
Sponsor
- Lead sponsor
- Lantern Pharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Participants will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patients will be monitored for safety, PK, and clinical activity
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
- GBM
- TNBC - Triple-Negative Breast Cancer
- NSCLC
- Pancreatic Adenocarcinoma
- DDR Gene Mutation
Interventions
LP-184Drug
LP-184 is a small molecule alkylating agent causing tumor cell death through DNA damage.
OlaparibDrug
A poly (ADP-ribose) polymerase (PARP) inhibitor that impairs homologous recombination (HR) dependent DNA damage repair by trapping PARP1/2 on DNA, leading to synthetic lethality in BRCA1/2-deficient cells.
Nivolumab & IpilimumabDrug
Nivolumab is monoclonal antibody and classified as an immune checkpoint inhibitor. By blocking the PD-1 receptor on the surface of T cells, Nivolumab restores immune cells' ability to recognize and attack cancer cells. Ipilimumab is monoclonal antibody and classified as an immune checkpoint inhibitor. By blocking the CTLA4 protein on the surface of T cells, Ipilimumab activates T-cells and allows T-cells to attack cancer cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of LP-184 assessed by the incidence and severity of all adverse events graded by CTCAE v5.0Time frame: 12 months
- To determine the MTD of LP-184 based on all available safety (graded by CTCAE v5.0) and PK data.Time frame: 12 months
- To determine the RP2D of LP-184 based on all available safety (graded by CTCAE v5.0), PK, PD and efficacy dataTime frame: 12 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Highlands Oncology Group
Springdale, Arkansas
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana
Norton Healthcare, Inc.
Louisville, Kentucky
John Hopkins - The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Fox Chase Cancer Center
Philadelphia, Pennsylvania
UT Health Science Center San Antonio
San Antonio, Texas
START Mountain Region
West Valley City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.